Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease

✍ Scribed by Theresa A. Zesiewicz; Kelly L. Sullivan; John L. Maldonado; William O. Tatum; Robert A. Hauser

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 69 KB
• Volume: 20
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.20563

✦ Synopsis

Abstract

We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society